Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01898 |
| Species: | Homo sapiens |
| Position : | chr9:14296620-14326255 |
| Year: | 2024 |
| Title: | Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer |
| Genome Build: | hg38 |
| Enhancer Type: | Super-enhancer |
| Condition: | Disease |
| Disease Name: | Kaposi sarcoma |
| PMID: | 39677680 |
| MONDO: | MONDO:0005082 |
| Tissue: | Skin |
| Tissue Ontology ID: | UBERON:0000014 |
| Cell Source: | Human Kaposi sarcoma cell line |
| CVCL ID: | CVCL_8250 |
| Cell Type: | Kaposi sarcoma cell |
| Cell Ontology ID: | CL:0002581 |
| Experiment Type: | Enhancer activity assay, Functional perturbation assay |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | Western blot, qRT-PCR |
| Target gene : | NFIB |
| TF name : | FOXA2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| FOXA2 | FOXA1 transcription factor network | pid | 45 |
| FOXA2 | FOXA2 and FOXA3 transcription factor networks | pid | 45 |
| FOXA2 | Hedgehog signaling events mediated by Gli proteins | pid | 49 |
| FOXA2 | Regulation of gene expression in beta cells | reactome | 17 |
| FOXA2 | Maturity onset diabetes of the young | kegg | 25 |
| FOXA2 | Hs_Endoderm_Differentiation_WP2853_88152 | wikipathways | 62 |
| FOXA2 | Hs_Dopaminergic_Neurogenesis_WP2855_87239 | wikipathways | 19 |
| FOXA2 | Hs_Heart_Development_WP1591_90186 | wikipathways | 28 |
| FOXA2 | Hs_Ectoderm_Differentiation_WP2858_89329 | wikipathways | 56 |